| Description | This product is a neutralizing antibody that binds to Severe Acute Respiratory Syndrome Coronavirus 2. S2X35 is capable of specifically binding with SARS-CoV-2 and shows a good capacity to neutralize the SARS-CoV-2. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | SARS-CoV-2 |
| Epitope | RBD receptor binding domain |
| Isotype | IgG1 |
| Expression Species | HEK293F or CHO cell line |
| Conjugation | Unconjugated |
| Purity | >95% |
| Endotoxin | <1 EU/mg |
| Form | Liquid |
| Purification | Protein A purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
| Application | ELISA |
| Application Notes | 96 half area well-plates were coated over-night at 4°C with 25 μL of sarbecoviruses RBD proteins at 5 μg/mL in PBS pH 7.2. Plates were blocked with PBS 1% BSA and subsequently incubated with mAb serial dilutions for 1 h at room temperature. After 4 washing steps with PBS-T, goat anti-human IgG secondary antibody was added and incubated for 1 h at room temperature. Plates were then washed 4 times with PBS-T and 4-NitroPhenyl phosphate substrate added. After 30 min incubation, absorbance at 405 nm was measured by a plate reader and data plotted using Prism GraphPad. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | SARS-CoV-2 |
| Alternative Name | Severe acute respiratory syndrome coronavirus 2 |
| Research Area | Coronavirus Disease 2019 |
| Related Disease | Coronavirus Disease 2019 |
